Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 13/20 | 0.67 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.38 |
| ▸ | CSF1R | P07333 | 4/20 | 0.38 |
| ▸ | BRD4 | O60885 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | BRD2 | P25440 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | BRD3 | Q15059 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4299675 | 0.87 | PDE4B (0.60) | PDE4BMTNR1BCSF1RBRD4CYP3A4 | |
| SCHEMBL4928534 | 0.86 | PDE4B (0.59) | PDE4BMTNR1BCSF1RBRD4CYP3A4 | |
| SCHEMBL1275589 | 0.85 | PDE4B (0.75) | PDE4BCSF1R | |
| SCHEMBL4298665 | 0.85 | PDE4B (0.58) | PDE4BMTNR1BCSF1RBRD4CYP3A4 | |
| SCHEMBL4949101 | 0.85 | PDE4B (0.68) | PDE4BMTNR1BCSF1R | |
| SCHEMBL4924230 | 0.85 | PDE4B (0.57) | PDE4BMTNR1BCSF1RBRD4CYP3A4 | |
| Hydrochloric Acid SCHEMBL2481486 | 0.85 | PDE4B (0.74) | PDE4BCSF1R | |
| SCHEMBL14168749 | 0.84 | PDE4B (0.58) | PDE4BMTNR1BCSF1RBRD4CYP3A4 | |
| SCHEMBL4299487 | 0.84 | PDE4B (0.59) | PDE4BMTNR1BCSF1RBRD4CYP3A4 | |
| SCHEMBL4949173 | 0.83 | PDE4B (0.69) | PDE4BMTNR1BCSF1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090270444-A1 | 1,7-Naphthyridines | GLAXO GROUP LIMITED (GB) | 2009-10-29 | — | — | US | claimed |
| EP-1812434-A2 | 1,7-NAPHTHYRIDINES AS PDE4 INHIBITORS | GLAXO GROUP LIMITED (GB) | 2007-08-01 | — | — | EP | claimed |
| WO-2006053784-A2 | 1,7-NAPHTHYRIDINES AS PDE4 INHIBITORS | GLAXO GROUP LIMITED (GB) | 2006-05-26 | — | — | WO | claimed |
| US-20090270444-A1 | 1,7-Naphthyridines | GLAXO GROUP LIMITED (GB) | 2009-10-29 | — | — | US | disclosed |
| US-20090270444-A1 | 1,7-Naphthyridines | GLAXO GROUP LIMITED (GB) | 2009-10-29 | — | — | US | disclosed |
| EP-1812434-A2 | 1,7-NAPHTHYRIDINES AS PDE4 INHIBITORS | GLAXO GROUP LIMITED (GB) | 2007-08-01 | — | — | EP | disclosed |
| WO-2006053784-A2 | 1,7-NAPHTHYRIDINES AS PDE4 INHIBITORS | GLAXO GROUP LIMITED (GB) | 2006-05-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090270444-A1 | 1,7-Naphthyridines | CYP2F1, CYP2S1, CYP1A1 | PDE4B 2570/4885MTNR1B 1527/4885CSF1R 2695/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.